Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) have announced preliminary results from their Asian Phase IIII MYRROR study in 122 patients for the treatment of myopic choroidal neovascularization (mCNV). Patients receiving the anti-VEGF treatment at a dose of 2 milligrams (mg), followed by treatment on an as-needed (PRN) basis, had a mean improvement in best-corrected visual acuity (BCVA) from baseline at week 24 of 12.1 letters, compared to a loss of 2.0 letters in patients receiving sham injections (p < 0.0001). The company additionally reported that the most common adverse events observed in the MYRROR trial, occurring with a frequency of 2% or more, were conjunctival hemorrhage, dry eye, eye pain, headache and nasopharyngitis.
Regeneron Pharmaceuticals Inc,. and Bayer Healthcare announce top-line data from Eylea Phase III MYRROR trial
- by swdadmin